For more information about AstraZeneca, please visitContact: Tracy Knudsen AstraZenecaAstraZeneca announced that SYMBICOR metered dose pressure inhaler is now for the United States available for long-term maintenance treatment of asthma in patients 12 years and older. Medications , and formoterol, a rapid and long-acting beta-2 – agonist For many patients, this combination treatment improved asthma control as early as one day, which is maintained over 12 weeks. Symbicort also provides improved lung function. Within 15 minutes after initiation of treatment Symbicort does not replace fast-acting inhalers for sudden attacks.
The safety profile of Symbicort is on a robust U.S. Development program, its safety in more than 6,000 patients with Symbicort in Phase I, II and III studies that were treated submitted to FDA were evaluated. Symbicort has safety of data from long-term studies of up to one year and a robust cardiac safety profile.Announced Phone Healthcare adds started Discharge Care Management the program In order COPD management to its rural population of include.
That cost of healthcare – We have seen that first-hand the accepts regular monitoring and regular monitoring and management through Tel – Assurance in patients with CHF, particularly those who living in rural areas, and to the improve outcomes and organizational prowess , said Dr. By Steve Linn, Chief Medical Officer of, South Jersey Healthcare. We extend our partnership, of our patients with COPD pay the same benefits and see a greater reduction of unnecessary hospitals recoveries.